Key takeaways for California
- • No GLP-1 is FDA-labeled for prediabetes — use is off-label.
- • Eligibility may still apply if BMI 30+ or 27+ with comorbidity (Wegovy/Zepbound).
- • Roughly 80-95% of prediabetic adults revert to normoglycemia in major trials.
- • Medi-Cal coverage rules apply for Prediabetes patients in California — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Prediabetes
No GLP-1 drug carries an FDA prediabetes indication. However, in obese prediabetic adults, Wegovy and Zepbound are approved on the basis of BMI/comorbidity criteria, and both have been shown in trial post-hoc analyses to convert prediabetes back to normoglycemia in the majority of treated patients. Evidence grade: B (extrapolation from RCT subgroups). Lifestyle therapy and metformin remain first-line per ADA. GLP-1 use specifically for prediabetes is off-label and should be discussed with a physician.
California-specific context
California has telehealth access concentrated in Los Angeles, San Diego, San Jose metros, with additional reach to San Francisco and Fresno. Kaiser Permanente, UCSF, Stanford Health, UCLA Health, Cedars-Sinai is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.cdph.ca.gov.
Californiatelehealth & pricing rules
- • California requires a live video consultation before a GLP-1 prescription.
- • California allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in California: ~$285/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.